Voyager Therapeutics (STU:VT6) Debt-to-Asset : 0.11 (As of Jun. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Voyager Therapeutics Debt-to-Asset?

Voyager Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €6.3 Mil. Voyager Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €37.4 Mil. Voyager Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was €405.3 Mil. Voyager Therapeutics's debt to asset for the quarter that ended in Jun. 2024 was 0.11.

Voyager Therapeutics Debt-to-Asset Historical Data

The historical data trend for Voyager Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Voyager Therapeutics Debt-to-Asset Chart

Voyager Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.10

0.18

0.23

0.15

0.06

Voyager Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Debt-to-Asset	Get a 7-Day Free Trial															0.07	0.07	0.06	0.10	0.11

Competitive Comparison of Voyager Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, Voyager Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Voyager Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Voyager Therapeutics's Debt-to-Asset falls into.

Voyager Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Voyager Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.934	+	15.674)	/	322.125
	=	0.06

Voyager Therapeutics's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(6.258	+	37.35)	/	405.253
	=	0.11

Voyager Therapeutics (STU:VT6) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Voyager Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Voyager Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Voyager Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Voyager Therapeutics Inc (STU:VT6) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

VYGR:USA VYGR:Mexico

Address

75 Hayden Avenue, Lexington, MA, USA, 02421

Website

https://www.voyagertherapeutics.com

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Voyager Therapeutics Headlines

No Headlines